Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome

Human Psychopharmacology

Volumn 20, Issue 7, 2005, Pages 511-519

  Favre, Jean Daniel ^a   Allain, Hervé ^b   Aubin, Henri Jean ^c   Frija Orvoen, Elisabeth ^d   Gillet, Claudine ^e   Lejoyeux, Michel ^f   Payen, Alain ^a   Weber, Michel ^g   Garcia Acosta, Stéphanie ^h   Kermadi, Imane ^h   Dib, Michel ⁱ   Garay, R Perso ^j  

^a PERCY MILITARY HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c Hôpitaux Universitaires Henri Mondor   (France)

^d HÔTEL DIEU   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f BICHAT HOSPITAL   (France)

^g Hopital Saint Julien Nancy   (France)

^h SANOFI   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j NONE   (France)

more..

Author keywords

Alcohol; Cyamemazine; Diazepam; Neuroleptics

Indexed keywords

CYAMEMAZINE; DIAZEPAM; PHENOTHIAZINE DERIVATIVE;

ADULT; ALCOHOLISM; ANALYTICAL ERROR; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; XEROSTOMIA;

ALCOHOL WITHDRAWAL DELIRIUM; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; DIAZEPAM; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; HYPNOTICS AND SEDATIVES; OXYGEN; PATIENT COMPLIANCE; PHENOTHIAZINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 27144464134     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.718     Document Type: Article

References (36)

1. Adinoff B. 1994. Double-blind study of aprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. Alcohol Clin Exp Res 18: 873-878.
2. Ajzenberg D. 1973. Utilisation d'un nouveau neuroleptique sédatif, la cyamémazine (Tercian®) dans l'alcoolisme. Psychol Méd (Paris) 5: 5-6.
3. 2C-receptor antagonist properties of cyamemazine: significance for its clinical anxiolytic activity. Psychopharmacology 147: 412-417.
4. Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP. 2002. 5-HT(2A) receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Eur J Pharmacol 454: 235-239.
5. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV). American Psychiatric Association: Washington, DC, 195-199.
6. American Psychiatric Association. 1995. Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry 152(S11): 1-80.
7. Archambault JC, Théodore F, Minne P. 1986. Utilisation du Tercian® en monothérapie dans l'alcoolisme chronique (à propos de 78 observations). Actual Psychiatr 10: 118-121.
8. Blum K, Eubanks JD, Wallace JE, Hamilton H. 1976. Enhancement of alcohol withdrawal convulsions in mice by haloperidol. Clin Toxicol 9: 427-434
9. Bourin M, Dailly E, Hascoet M. 2004 Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev 10: 219-229.
10. Bourin M, Dhonnchadha BAN, Colombel MC, Dib M, Hascoët M. 2001. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 124: 87-95.
11. Brailowsky S, Garcia O. 1999. Ethanol, GABA and epilepsy. Arch Med Res 30: 3-9.
12. De Witte P, Pinto E, Ansseau M, Verbanck P. 2003. Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biohav Rev 27: 189-197.
13. Favre JD, Garcia-Acosta S, Kermadi I, Dib M. 2004. Clinical efficacy of cyamemazine vs diazepam in the alcohol withdrawal syndrome. XXIV CINP Congress. Paris. June 20-24, 2004. Cambridge University Press: Cambridge, UK.
14. Gatch MB, Lal H. 1998. Pharmacological teatment of alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 22: 917-944.
15. Glue P, Nutt D. 1990. Overexcitement and disinhibition. Dynamic neurotransmitter interactions in alcohol withdrawal. Br J Psychiatry 157: 491-499.
16. Gury C, Berchot F, Fabre C, Surugue J, Welcomme N. 2000. Analyse des prescriptions de neuroleptiques dans cinq centres hospitaliers spécialisés. Comparaisons entre prescriptions hospitalières et prescriptions de sortie. Inf Psychiatr 76: 954-963.
17. Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M. 2003. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol 65: 435-440.
18. Hode Y, Reimold M, Demazieres A, et al. 2005. A positron émission tomography (PET) study of cerebral dopamine (D(2) and serotonine 5-HT(2A) receptor occupancy in patients treated with cyamemazine (Tercian). Psychopharmacology (Berlin) 180: 377-384.
19. Jobe PC, Dailey JW, Wernicke JF. 1999. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 13: 317-356.
20. Kaim SC, Klett CJ, Rothfeld B. 1969. Treatment of alcohol withdrawal state: a comparison of four drugs. Am J Psychiatry 125: 1640-1646.
21. Kosten TR, O'Connor PG. 2003. Management of drug and alcohol withdrawal. N Engl J Med 348: 1786-1795.
22. Naassila M, Legrand E, d'Alché-Birée F, Daoust M. 1998. Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice. Psychopharmacology 140: 421-428.
23. Naranjo CA, Seller EM, Chater K, Iversen P, Roach C, Sykora K. 1982. Importance of nonpharmacologic interventions in the treatment of acute alcohol withdrawal. Clin Pharmacol Ther 31: 254-255.
24. Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M. 2003. Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine. Naunyn Schmiedebergs Arch Pharmacol 367: 134-139.
25. Peters DH, Faulds D. 1994. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 47: 1010-1032.
26. Radat F. 1995. Cyamémazine: traitement symptomatique des dimensions anxieuses, impulsives et agressives. Inf Psychiatr 10: 967-968.
27. Saitz R, O'Malley S. 1997. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am 81: 881-907.
28. Salgado-Commissariat D, Alkadhi KA. 1997. Serotonin inhibits epileptiform discharge by activation of 5-HT1A receptors in CA1 pyramidal neurons. Neuropharmacology 36: 1705-1712.
29. Scatton B, Cohen C, Perrault G, et al. 2001. The preclinical pharmacologic profile of tiapride. Eur Psychiatry 16(Suppl. 1): 29-34.
30. Sellers EM, Naranjo CA, Harrison M, Devenyl P, Roach C, Sykora K. 1983. Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther 34: 822-826.
31. Shaw JM, Kolesar GS, Sellers EM, Kaplan HL, Sandor P. 1981. Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1: 382-389.
32. Sullivan JT, Sykora K, Scheiderman J, Naranjo CA, Sellers EM. 1989. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) Br J Addict 84: 1353-1357.
33. Tokarski K, Zahorodna A, Bobula B, Hess G. 2002. Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat. Exp Brain Res 147: 505-510.
34. Uzbay IT, Akarsu ES, Kayaalp SO. 1994. Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats. Pharmacol Biochem Behav 49: 969-974.
35. Vidal (French Desk Reference Dictionary) 2002. Tercian®.
36. Yu L, Fisher H, Wagner GC. 2000. Monoaminergic changes associated with audiogenic seizures in ethanol-dependent rats. Prog Neuropsychopharmacol Biol Psychiatry 24: 1379-1392.